Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer
This study validated the feasibility of the circRNA-electroporation strategy in CAR-T cell therapy and offered a potentially effective approach for treating SCLC, highlighting the potential of circRNA-based technologies in advancing cell therapies.
Authors
- Xiao Li (ORCID: https://orcid.org/0000-0001-9785-4907)
- Shaoyi Chen (ORCID: https://orcid.org/0000-0003-2253-5041)
- Jun Wang (ORCID: https://orcid.org/0000-0002-9733-1433)
- Shaodong Wang
- Mantang Qiu
- Haoran Li (ORCID: https://orcid.org/0009-0005-2375-9188)
- Xun Wang (ORCID: https://orcid.org/0000-0002-2981-4740)
- Zheng Liu (ORCID: https://orcid.org/0000-0002-3538-9349)
- Jingwei Zhang (ORCID: https://orcid.org/0000-0002-0855-7327)
- Ming Sun (ORCID: https://orcid.org/0000-0002-1173-2288)
- Yang Feng (ORCID: https://orcid.org/0000-0002-9012-2460)
- Yun Li (ORCID: https://orcid.org/0009-0002-5707-5647)
- Jingsheng Cai
- Kezhong Chen
Institutions
- University of Electronic Science and Technology of China (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Suzhou Municipal Hospital (CN)
- Sichuan Cancer Hospital (CN)
- Peking University People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1186/s40164-025-00625-8
- Citations
- 16
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 16.73
Funders
- National Natural Science Foundation of China
- Beijing Nova Program
- National Key Research and Development Program of China